Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

YB-1 Expression and Phosphorylation Regulate Tumorigenicity and Invasiveness in Melanoma by Influencing EMT.

Kosnopfel C, Sinnberg T, Sauer B, Busch C, Niessner H, Schmitt A, Forchhammer S, Grimmel C, Mertens PR, Hailfinger S, Dunn SE, Garbe C, Schittek B.

Mol Cancer Res. 2018 May 9. doi: 10.1158/1541-7786.MCR-17-0528. [Epub ahead of print]

PMID:
29743296
2.

Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells.

Sinnberg T, Niessner H, Levesque MP, Dettweiler C, Garbe C, Busch C.

Biol Open. 2018 May 1. pii: bio.032656. doi: 10.1242/bio.032656. [Epub ahead of print]

3.

Inhibiting HSP90 prevents the induction of myeloid-derived suppressor cells by melanoma cells.

Janssen N, Speigl L, Pawelec G, Niessner H, Shipp C.

Cell Immunol. 2018 May;327:68-76. doi: 10.1016/j.cellimm.2018.02.012. Epub 2018 Feb 21.

PMID:
29478948
4.

Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype.

Sinnberg T, Levesque MP, Krochmann J, Cheng PF, Ikenberg K, Meraz-Torres F, Niessner H, Garbe C, Busch C.

Mol Cancer. 2018 Feb 17;17(1):59. doi: 10.1186/s12943-018-0773-5.

5.

Genomics of Immunotherapy-Associated Hyperprogressors-Letter.

Forschner A, Niessner H, Möller Y, Horak P, Fröhlich M, Warsow G, Stenzinger A, Fröhling S, Glimm H, Klumpp B, Garbe C, Sinnberg T.

Clin Cancer Res. 2017 Oct 15;23(20):6374-6375. doi: 10.1158/1078-0432.CCR-17-1480. No abstract available.

PMID:
29030332
6.

BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.

Niessner H, Sinnberg T, Kosnopfel C, Smalley KSM, Beck D, Praetorius C, Mai M, Beissert S, Kulms D, Schaller M, Garbe C, Flaherty KT, Westphal D, Wanke I, Meier F.

Clin Cancer Res. 2017 Oct 15;23(20):6203-6214. doi: 10.1158/1078-0432.CCR-17-0098. Epub 2017 Jul 19.

PMID:
28724666
7.

Molecular insights into melanoma brain metastases.

Westphal D, Glitza Oliva IC, Niessner H.

Cancer. 2017 Jun 1;123(S11):2163-2175. doi: 10.1002/cncr.30594. Review.

PMID:
28543697
8.

Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1.

Niessner H, Kosnopfel C, Sinnberg T, Beck D, Krieg K, Wanke I, Lasithiotakis K, Bonin M, Garbe C, Meier F.

Exp Dermatol. 2017 Jul;26(7):598-606. doi: 10.1111/exd.13372.

PMID:
28423208
9.

Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase.

Kosnopfel C, Sinnberg T, Sauer B, Niessner H, Schmitt A, Makino E, Forschner A, Hailfinger S, Garbe C, Schittek B.

Oncotarget. 2017 May 30;8(22):35761-35775. doi: 10.18632/oncotarget.16204.

10.

The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition.

Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, Garbe C.

Eur J Cancer. 2017 Mar;73:85-92. doi: 10.1016/j.ejca.2016.12.010. Epub 2017 Feb 3. Review.

PMID:
28169047
11.

MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition.

Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, Garbe C.

Eur J Cancer. 2017 Mar;73:93-101. doi: 10.1016/j.ejca.2016.12.012. Epub 2017 Feb 3. Review.

PMID:
28162869
12.

PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.

Niessner H, Schmitz J, Tabatabai G, Schmid AM, Calaminus C, Sinnberg T, Weide B, Eigentler TK, Garbe C, Schittek B, Quintanilla-Fend L, Bender B, Mai M, Praetorius C, Beissert S, Schackert G, Muders MH, Meinhardt M, Baretton GB, Dummer R, Flaherty K, Pichler BJ, Kulms D, Westphal D, Meier F.

Clin Cancer Res. 2016 Dec 1;22(23):5818-5828. Epub 2016 Jun 15. Erratum in: Clin Cancer Res. 2017 Mar 1;23 (5):1361.

13.

A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib.

Sinnberg T, Makino E, Krueger MA, Velic A, Macek B, Rothbauer U, Groll N, Pötz O, Czemmel S, Niessner H, Meier F, Ikenberg K, Garbe C, Schittek B.

EBioMedicine. 2016 Jun;8:132-149. doi: 10.1016/j.ebiom.2016.04.037. Epub 2016 May 1.

14.

PTEN regulates IGF-1R-mediated therapy resistance in melanoma.

Wang J, Sinnberg T, Niessner H, Dölker R, Sauer B, Kempf WE, Meier F, Leslie N, Schittek B.

Pigment Cell Melanoma Res. 2015 Sep;28(5):572-89. doi: 10.1111/pcmr.12390.

PMID:
26112748
15.

Molecular mechanisms of pharmacological doses of ascorbate on cancer cells.

Venturelli S, Sinnberg TW, Niessner H, Busch C.

Wien Med Wochenschr. 2015 Jun;165(11-12):251-7. doi: 10.1007/s10354-015-0356-7. Epub 2015 Jun 12. Review.

PMID:
26065536
16.

Epigenetic impacts of ascorbate on human metastatic melanoma cells.

Venturelli S, Sinnberg TW, Berger A, Noor S, Levesque MP, Böcker A, Niessner H, Lauer UM, Bitzer M, Garbe C, Busch C.

Front Oncol. 2014 Aug 25;4:227. doi: 10.3389/fonc.2014.00227. eCollection 2014.

17.

[Prevention of venous thromboembolism in musculoskeletal surgery].

Pabinger-Fasching I, Eichinger-Hasenauer S, Grohs J, Hochreiter J, Kastner N, Korninger HC, Kozek-Langenecker S, Marlovits S, Niessner H, Rachbauer F, Ritschl P, Wurnig C, Windhager R.

Wien Klin Wochenschr. 2014 May;126(9-10):298-310. doi: 10.1007/s00508-014-0509-5. Epub 2014 May 14. German.

PMID:
24825594
18.

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.

Niessner H, Forschner A, Klumpp B, Honegger JB, Witte M, Bornemann A, Dummer R, Adam A, Bauer J, Tabatabai G, Flaherty K, Sinnberg T, Beck D, Leiter U, Mauch C, Roesch A, Weide B, Eigentler T, Schadendorf D, Garbe C, Kulms D, Quintanilla-Martinez L, Meier F.

Cancer Med. 2013 Feb;2(1):76-85. doi: 10.1002/cam4.50. Epub 2013 Feb 3.

19.

Successful treatment with vemurafenib in BRAF V600K-positive cerebral melanoma metastasis.

Forschner A, Niessner H, Bauer J, Bender B, Garbe C, Meier F.

JAMA Dermatol. 2013 May;149(5):642-4. doi: 10.1001/jamadermatol.2013.372. No abstract available.

PMID:
23677116
20.

T-helper-1-cell cytokines drive cancer into senescence.

Braumüller H, Wieder T, Brenner E, Aßmann S, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C, Ranta F, Ullrich S, Mocikat R, Braungart K, Mehra T, Fehrenbacher B, Berdel J, Niessner H, Meier F, van den Broek M, Häring HU, Handgretinger R, Quintanilla-Martinez L, Fend F, Pesic M, Bauer J, Zender L, Schaller M, Schulze-Osthoff K, Röcken M.

Nature. 2013 Feb 21;494(7437):361-5. doi: 10.1038/nature11824. Epub 2013 Feb 3.

21.

Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells.

Beck D, Niessner H, Smalley KS, Flaherty K, Paraiso KH, Busch C, Sinnberg T, Vasseur S, Iovanna JL, Drießen S, Stork B, Wesselborg S, Schaller M, Biedermann T, Bauer J, Lasithiotakis K, Weide B, Eberle J, Schittek B, Schadendorf D, Garbe C, Kulms D, Meier F.

Sci Signal. 2013 Jan 29;6(260):ra7. doi: 10.1126/scisignal.2003057.

22.

Resource planning for ambulance services in mass casualty incidents: a DES-based policy model.

Rauner MS, Schaffhauser-Linzatti MM, Niessner H.

Health Care Manag Sci. 2012 Sep;15(3):254-69. doi: 10.1007/s10729-012-9198-7. Epub 2012 Jun 1.

PMID:
22653522
23.

Cytotoxicity of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluor-2'-deoxyuridine against human melanoma cells.

Schott S, Niessner H, Sinnberg T, Venturelli S, Berger A, Ikenberg K, Villanueva J, Meier F, Garbe C, Busch C.

Int J Cancer. 2012 Nov 1;131(9):2165-74. doi: 10.1002/ijc.27476. Epub 2012 Mar 15.

24.

The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.

Niessner H, Beck D, Sinnberg T, Lasithiotakis K, Maczey E, Gogel J, Venturelli S, Berger A, Mauthe M, Toulany M, Flaherty K, Schaller M, Schadendorf D, Proikas-Cezanne T, Schittek B, Garbe C, Kulms D, Meier F.

J Invest Dermatol. 2011 Feb;131(2):468-79. doi: 10.1038/jid.2010.297. Epub 2010 Oct 14.

25.

Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide.

Sinnberg T, Lasithiotakis K, Niessner H, Schittek B, Flaherty KT, Kulms D, Maczey E, Campos M, Gogel J, Garbe C, Meier F.

J Invest Dermatol. 2009 Jun;129(6):1500-15. doi: 10.1038/jid.2008.379. Epub 2008 Dec 11.

26.

[Austrian Guidelines for Prophylaxis of Venous Thromboembolism].

Pabinger I, Eichinger S, Minar E, Niessner H.

Wien Klin Wochenschr. 2007;119(23-24):739-46. German.

PMID:
18157609
27.

Traveller's thrombosis 2001.

Partsch H, Niessner H, Bergau L, Blättler W, Cerny J, Gerlach H, Haas P, Haas S, Hirschl M, Korninger H, Kyrle P, Landgraf H, Mahler F, Minar E, Pabinger I, Prinz A, Rabe E, Radner A, Ramelet AA, Schobersberger W, Schuller-Petrovic S, Stöberl Ch, Zinnagl N.

Vasa. 2002 Feb;31(1):66-7. No abstract available.

PMID:
11951702
28.

[Low molecular weight heparins in acute coronary syndrome].

Huber K, Niessner A, Niessner H.

Herz. 2001 Apr;26 Suppl 1:53-60. German.

PMID:
11349628
29.

[Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions].

Niessner A, Niessner H, Huber K.

Herz. 2001 Apr;26 Suppl 1:36-41. German.

PMID:
11349625
30.

Interferon-alpha for the treatment of elderly patients with chronic myeloid leukaemia.

Hilbe W, Apfelbeck U, Fridrik M, Bernhart M, Niessner H, Abbrederis K, Michlmayr G, Pont J, Linkesch W, Hausmaninger H, Arneitz K, Baldinger C, Duba C, Eisterer W, Greil R, Konwalinka G, Niederwieser D, Gastl G, Thaler J.

Leuk Res. 1998 Oct;22(10):881-6.

PMID:
9766747
31.

Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II study.

Thaler J, Hilbe W, Apfelbeck U, Linkesch W, Sill H, Seewann H, Pont J, Bernhart M, Stöger M, Niessner H, Abbrederis K, Geissler D, Hausmaninger H, Lin W, Ludwig H, Lang A, Duba C, Fluckinger T, Greil R, Grünewald K, Konwalinka G, Niederwieser D, Fridrik M.

Leuk Res. 1997 Jan;21(1):75-80.

PMID:
9029189
32.

Relation of fibrinogen to presence and severity of coronary artery disease is independent of other coexisting heart disease. The ECAT Angina Pectoris Study Group.

Bolibar I, Kienast J, Thompson SG, Matthias R, Niessner H, Fechtrup C.

Am Heart J. 1993 Jun;125(6):1601-5.

PMID:
8498300
33.

Hereditary deficiency of antithrombin III, protein C and protein S: prevalence in patients with a history of venous thrombosis and criteria for rational patient screening.

Pabinger I, Brücker S, Kyrle PA, Schneider B, Korninger HC, Niessner H, Lechner K.

Blood Coagul Fibrinolysis. 1992 Oct;3(5):547-53.

PMID:
1450321
34.

Coincidence of acquired factor-X deficiency and disseminated intravascular coagulation in patients with acute nonlymphoblastic leukemia.

Pabinger I, Bettelheim P, Dudczak R, Hinterberger W, Kyrle PA, Niessner H, Schwarzinger I, Speiser W, Lechner K.

Ann Hematol. 1991 May;62(5):174-9.

PMID:
2049464
35.

Activation of coagulation and fibrinolysis in patients with arteriosclerosis: relation to localization of vessel disease and risk factors.

Speiser W, Speiser P, Minar E, Korninger C, Niessner H, Huber K, Schernthaner G, Ehringer H, Lechner K.

Thromb Res. 1990 Jul 1;59(1):77-88.

PMID:
2144671
36.

IIB von Willebrand's disease: pathogenetic and therapeutic studies.

Kyrle PA, Niessner H, Dent J, Panzer S, Brenner B, Zimmerman TS, Lechner K.

Br J Haematol. 1988 May;69(1):55-9.

PMID:
3132965
37.

[Home treatment in hemophilia].

Pabinger I, Niessner H, Korninger C, Nowotny C, Stain M, Kyrle PA, Lechner K.

Wien Klin Wochenschr. 1987 Nov 20;99(22):773-7. German.

PMID:
3124354
38.

Protein C- and coagulation factor levels during the initial phase of oral anticoagulant therapy (low dose regimen) in a patient with heterozygous protein C deficiency.

Pabinger-Fasching I, Lechner K, Niessner H, Korninger C, Kyrle PA.

Thromb Res. 1987 Sep 15;47(6):705-8. No abstract available.

PMID:
3686485
39.

[Oral anticoagulant therapy--renaissance of an old therapy?].

Lechner K, Korninger C, Kyrle P, Geissler K, Niessner H, Pabinger I, Panzer S, Gössinger H, Bettelheim P, Hinterberger W.

Wien Klin Wochenschr. 1987 Apr 3;99(7):203-10. German.

PMID:
3590801
40.

[Right heart failure as a clinical sign of pulmonary artery sarcoma].

Bettelheim P, Hochmeister M, Herold C, Eichler HG, Korninger C, Panzer S, Niessner H, Korn A, Holzner JH, Lechner K.

Wien Klin Wochenschr. 1987 Mar 6;99(5):156-9. German.

PMID:
3577189
41.

Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates.

Schwarzinger I, Pabinger I, Korninger C, Haschke F, Kundi M, Niessner H, Lechner K.

Am J Hematol. 1987 Mar;24(3):241-5.

PMID:
3103425
42.

[Use of genetic technics in medical diagnosis exemplified by hemophilia A].

Wintersberger E, Ogris E, Niessner H, Lechner K.

Wien Klin Wochenschr. 1987 Feb 20;99(4):108-11. German.

PMID:
2883776
43.

Thromboembolism in patients with prosthetic heart valves. An adequately controlled intense anticoagulant therapy and its influence on the occurrence of thromboembolism in relation to valve type.

Gössinger H, Niessner H, Grubeck B, Mösslacher H, Bettelheim P, Lechner K, Mlczoch J, Domanig E.

Thorac Cardiovasc Surg. 1986 Oct;34(5):283-6.

PMID:
2431498
44.
45.

Acquired thrombasthenia due to GPIIb/IIIa-specific platelet autoantibodies.

Niessner H, Clemetson KJ, Panzer S, Mueller-Eckhardt C, Santoso S, Bettelheim P.

Blood. 1986 Aug;68(2):571-6.

46.

Coumarin induced acral skin necrosis associated with hereditary protein C deficiency.

Pabinger I, Karnik R, Lechner K, Slany J, Niessner H.

Blut. 1986 Jun;52(6):365-70.

PMID:
3755068
47.

Increased risk of thrombosis due to abnormalities of the hemostatic system.

Lechner K, Pabinger-Fasching I, Korninger C, Niessner H.

Behring Inst Mitt. 1986 Feb;(79):1-8.

PMID:
3718401
48.
49.

Treatment of severe aplastic anemia with combined immunosuppression (antithymocyte globulin and high-dose methylprednisolone).

Hinterberger-Fischer M, Hinterberger W, Höckern P, Schmidmeier W, Gadner H, Geissler K, Kos M, Schwarzinger I, Neumann E, Niessner H, et al.

Acta Haematol. 1986;76(4):196-201.

PMID:
3107306
50.

Immune thrombocytopenia in severe hemophilia A treated with high-dose intravenous immunoglobulin.

Panzer S, Zeitelhuber U, Hach V, Brackmann HH, Niessner H, Mueller-Eckhardt C.

Transfusion. 1986 Jan-Feb;26(1):69-72.

PMID:
3080831

Supplemental Content

Loading ...
Support Center